ABIVAX SA (2X1.DE) Stock Price, Forecast & Analysis
FRA:2X1 • FR0012333284
2X1.DE Key Statistics, Chart & Performance
The current stock price of 2X1.DE is 106 EUR. In the past month the price increased by 1.92%.
2X1.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 2X1.DE.
2X1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to 2X1.DE. 2X1.DE has a bad profitability rating. Also its financial health evaluation is rather negative.
2X1.DE Financial Highlights
Over the last trailing twelve months 2X1.DE reported a non-GAAP Earnings per Share(EPS) of -2.8. The EPS increased by 18.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -146.87% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
2X1.DE Forecast & Estimates
14 analysts have analysed 2X1.DE and the average price target is 127.99 EUR. This implies a price increase of 20.75% is expected in the next year compared to the current price of 106.
For the next year, analysts expect an EPS growth of -20.7% and a revenue growth 91.53% for 2X1.DE
2X1.DE Ownership
2X1.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.11 | 43.863B | ||
| 1AE | ARGENX SE | 27.99 | 43.776B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.869B | ||
| ABVX | ABIVAX SA | N/A | 8.398B | ||
| GXE | GALAPAGOS NV | N/A | 1.882B | ||
| GLPG | GALAPAGOS NV | N/A | 1.869B | ||
| 6IV | INVENTIVA SA | N/A | 1.112B | ||
| IVA | INVENTIVA SA | N/A | 1.092B | ||
| NANO | NANOBIOTIX | N/A | 1.006B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 2X1.DE
Company Profile
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Info
ABIVAX SA
7-11 Boulevard Haussmann
Paris ILE-DE-FRANCE FR
Employees: 69
Phone: 33153830963
ABIVAX SA / 2X1.DE FAQ
What does ABIVAX SA do?
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
What is the stock price of ABIVAX SA today?
The current stock price of 2X1.DE is 106 EUR. The price increased by 8.05% in the last trading session.
Does 2X1 stock pay dividends?
2X1.DE does not pay a dividend.
How is the ChartMill rating for ABIVAX SA?
2X1.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for ABIVAX SA?
ABIVAX SA (2X1.DE) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for 2X1 stock?
ABIVAX SA (2X1.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.8).
When does ABIVAX SA (2X1.DE) report earnings?
ABIVAX SA (2X1.DE) will report earnings on 2026-03-23, after the market close.